Infliximab is indicated for the treatment of inflammatory conditions in Rheumatology, Gastroenterology, and Dermatology2.

Infliximab is a cornerstone treatment for many inflammatory diseases - with more than 15 years of clinical experience5,7-12.

Infliximab Approval Timeline

 

Infliximab is recommended for use in appropriate patients by European and UK Expert groups (ECCO13, NICE57, BSG59 and BSR60).

The use of Inflectra®/CT-P13* in inflammatory disease is supported by a rapidly growing body of clinical evidence and experience22,42,45.

 

Inflectra® Evidence

Approved in more than 80 countries worldwide24.

Inflectra Clinical Evidence

Please refer to the useful resources section to read more about the studies.

†Remicade® is a registered trademark of MSD.
Cumulative exposure from August 1998 through August 2016. Uses include rheumatoid arthritis, Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and ulcerative colitis.
*CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA®.

CD, Crohn’s disease; TNFi, Tumour necrosis factor inhibitor; US, United States; EU, European Union; ECCO, European Crohn's and Colitis Organisation; NICE, The National Institute for Health and Care Excellence; BSG, British Society of Gastroenterology; BSR, British Society of Rheumatology; DB, Double blind; RCTs, Randomised controlled trials; RA, Rheumatoid arthritis; AS, Ankylosing spondylitis; IBD, Inflammatory bowel disease; UC, Ulcerative colitis; TDM, Therapeutic drug monitoring.

 

PP-IFA-GBR-0322. December 2018